Thursday - July 30, 2026
Goodwin Guides CRISPR Therapeutics on Pricing $550 Million Upsized Convertible Senior Notes Offering
March 12, 2026
BOSTON, Massachusetts, March 12 [Category: BizLaw/Legal] -- Goodwin, a law firm, issued the following news release:

* * *

Goodwin Guides CRISPR Therapeutics on Pricing $550 Million Upsized Convertible Senior Notes Offering

*

The Life Sciences and Equity-Linked Capital Markets teams guided CRISPR Therapeutics AG (the "Company") on the pricing of $550 million aggregate principal amount of its convertible senior notes due 2031 (the " . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Click here for more information about our products